Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
3.200
+0.010 (0.31%)
Dec 24, 2024, 12:57 PM EST - Market closed
Daré Bioscience Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Daré Bioscience stock have an average target of 20.33, with a low estimate of 12 and a high estimate of 36. The average target predicts an increase of 535.31% from the current stock price of 3.20.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for DARE stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +275.00% | Dec 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +275.00% | Nov 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +275.00% | Oct 24, 2024 |
| Jones Trading | Jones Trading | Strong Buy Maintains $5 → $13 | Strong Buy | Maintains | $5 → $13 | +306.25% | Aug 16, 2024 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 14, 2024 |
Financial Forecast
Revenue This Year
1.41M
from 2.81M
Decreased by -49.78%
Revenue Next Year
3.34M
from 1.41M
Increased by 136.52%
EPS This Year
-0.54
from -4.15
EPS Next Year
-2.60
from -0.54
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 4.3M | 10.3M | 44.2M | |||
| Avg | 1.4M | 3.3M | 21.5M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 52.3% | 630.4% | 1,225.5% | |||
| Avg | -49.8% | 136.5% | 543.8% | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.43 | -1.49 | -0.27 | |||
| Avg | -0.54 | -2.60 | -1.36 | |||
| Low | -0.63 | -3.92 | -2.36 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.